HighGravityDataAmgen — Aug 5, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-25-000054
Showing in the filing
EPS (non-GAAP basis)
“$20.20 to $21.30”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 8
Dividend for Q2 FY2025
“$2.38 per share”
Total revenues for FY2025
“$35.0 billion to $36.0 billion”
EPS (GAAP basis) for FY2025
“$10.97 to $12.11”
Tax rate (GAAP basis) for FY2025
“11.0% to 12.5%”
EPS (non-GAAP basis) for FY2025
“$20.20 to $21.30”
Tax rate (non-GAAP basis) for FY2025
“14.5% to 16.0%”
Capital expenditures for FY2025
“approximately $2.3 billion”
Share repurchases for FY2025
“not to exceed $500 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
$Billions, except shares Q2 ’25 Q2 ’24 YOY Δ Operating Cash Flow $ 2.3 $ 2.5 $ (0.2) Capital Expenditures $ 0.4 $ 0.2 $ 0.1 Free Cash Flow $ 1.9 $ 2.2 $ (0.3) Dividends Paid $ 1.3 $ 1.2 $ 0.1 Share Repurchases $ 0.0 $ 0.0 $ 0.0 Average Diluted Shares (millions) 541 541 0 Note: Numbers may not add due to rounding AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 6/30/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 8.0 $ 12.0 $ (3.9) Debt Outstanding $ 56.2 $ 60.1 $ (3.9) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $35.0 billion to $36.0 billion. • On a GAAP basis, EPS in the range of $10.97 to $12.11, and a tax rate in the range of 11.0% to 12.5%. • On a non-GAAP basis, EPS in the range of $20.20 to $21.30, and a tax rate in the range of 14.5% to 16.0%. • Capital expenditures to be approximately $2.3 billion. • Share repurchases not to exceed $500 million. This guidance includes the estimated impact of implemented tariffs, but does not account for any tariffs or potential pricing actions announced or described but not implemented as well as any tariffs, sector specific tariffs, or pricing actions that could be implemented in the future. Second Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated peptide-antibody conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). • In June, the underlying details from Part 1 of the Phase 2 study of MariTide and complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented at the American Diabetes Association 85th Scientific Sessions and simultaneously published in the New England Journal
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.